首頁 > 市場調查報告書 > 製藥

癌症婦科治療

脂質體阿黴素市場規模、佔有率及成長分析（按產品類型、應用、分銷管道和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1902323

脂質體阿黴素市場規模、佔有率及成長分析（按產品類型、應用、分銷管道和地區分類）－2026-2033年產業預測

Liposomal Doxorubicin Market Size, Share, and Growth Analysis, By Product Type (Lipodox, Doxil), By Application (Breast Cancer, Ovarian Cancer), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月22日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球脂質體阿黴素市場規模預計在 2024 年達到 12.8 億美元，從 2025 年的 13.6 億美元成長到 2033 年的 22.4 億美元，在預測期（2026-2033 年）內複合年成長率為 6.4%。

由於肉瘤發病率上升以及脂質體阿黴素在治療包括乳癌和卵巢癌在內的多種癌症方面的療效，脂質體阿黴素市場正經歷強勁成長。這種封裝在脂質球中的製劑提高了藥物傳遞效率，從而推動了市場需求。關鍵成長要素包括醫療基礎設施的改善、醫療費用支出的增加、患者對治療方案認知度的提高以及學名藥的廣泛普及。然而，學名藥競爭加劇和監管要求的嚴格性可能會對市場擴張構成挑戰。儘管如此，由於人們對有效治療方案的認知度提高以及公共和私營部門投資的增加，該行業的盈利預計將會提升。此外，肝細胞癌發生率的上升以及某些癌症類型傳統治療方法的局限性也進一步推動了對脂質體阿黴素的需求。

全球脂質體阿黴素市場促進因素

脂質體阿黴素的全球市場主要受其在乳癌治療領域的應用推動，在許多國家都呈現顯著成長。製劑的持續創新是該藥物日益普及的主要因素。此外，標靶治療藥物需求的不斷成長以及化療依賴程度的日益提高，也進一步刺激了市場需求。私部門在該領域的投資增加也推動了市場擴張。同時，政府為加強醫療保健產業所採取的舉措，在提升脂質體阿黴素的全球市場佔有率方面發揮關鍵作用，從而推動了市場成長。

限制全球脂質體阿黴素市場的因素

由於多種藥物相關副作用，全球脂質體阿黴素市場可能面臨重大挑戰。患者在治療前後可能出現感染疾病風險增加、呼吸困難、蒼白、容易瘀青、頻繁流鼻血和全身疲倦等症狀。其他副作用包括手腳發紅、疼痛和脫皮，以及體重減輕、腹瀉和疲勞。這些併發症可能導致患者放棄治療，並使醫療專業人員不願開立脂質體阿黴素處方，最終阻礙市場成長。

全球脂質體阿黴素市場趨勢

全球脂質體阿黴素市場呈現顯著上升趨勢，主要促進因素是乳癌發生率的不斷攀升，乳癌是全球女性癌症診斷的主要類型。標靶藥物遞送系統日益受到關注和技術進步，以及脂質體製劑因其更高的生物利用度和更低的副作用而日益受到青睞，這些因素共同推動了市場成長。此外，脂質體阿黴素治療乳癌以外的其他多種惡性腫瘤的療效研究也在不斷深入，進一步拓展了其應用範圍。這種不斷變化的市場格局表明，脂質體阿黴素領域具有持續成長的巨大潛力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Johnson & Johnson（USA）
Sun Pharmaceutical Industries Ltd.（India）
Pfizer Inc.（USA）
Merck & Co., Inc.（USA）
Cipla Inc.（India）
Cadila Pharmaceuticals（India）
SRS Pharmaceuticals Pvt. Ltd.（India）
Teva Pharmaceutical Industries Ltd.（Israel）
Gilead Sciences, Inc.（USA）
Baxter International Inc.（USA）
Novartis AG（Switzerland）
F. Hoffmann-La Roche AG（Switzerland）
Bristol-Myers Squibb Company（USA）
Mylan NV（USA）
Sanofi SA（France）
Eli Lilly and Company（USA）
GlaxoSmithKline plc（UK）
AstraZeneca plc（UK）
Amgen Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）

結論與建議

簡介目錄

Product Code: SQMIG35I2216

Global Liposomal Doxorubicin Market size was valued at USD 1.28 Billion in 2024 and is poised to grow from USD 1.36 Billion in 2025 to USD 2.24 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).

The liposomal doxorubicin market is experiencing robust growth driven by the rising incidence of sarcoma and its effectiveness in treating various cancers, including breast and ovarian cancer. This formulation, encapsulated in a lipid sphere, enhances drug delivery, spurring demand. Key growth factors include advancements in healthcare infrastructure, escalating healthcare expenditures, heightened patient awareness regarding treatment options, and the proliferation of generic alternatives. However, intensified competition from generics and stringent regulatory requirements may pose challenges to market expansion. Nonetheless, the sector's profitability is expected to flourish due to increased awareness of viable treatment alternatives and growing investments from both public and private sectors. Additionally, rising incidences of hepatocellular carcinoma and challenges in previous treatments for specific cancers further boost demand for liposomal doxorubicin.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liposomal Doxorubicin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liposomal Doxorubicin Market Segments Analysis

Global Liposomal Doxorubicin Market is segmented by Product Type, Application, Distribution Channel and region. Based on Product Type, the market is segmented into Lipodox, Doxil and Myocet. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, Multiple Myeloma, Kaposi's Sarcoma and Other Cancers. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liposomal Doxorubicin Market

The global market for liposomal doxorubicin is significantly driven by its primary application in breast cancer treatment, which is witnessing alarming growth in numerous countries. A key factor contributing to the rising popularity of this drug is the ongoing innovation in formulations. Moreover, there is an increasing demand for pharmaceuticals designed for targeted therapies, coupled with a growing reliance on chemotherapy. Private sector investments in this area are also escalating, further supporting market expansion. Additionally, government initiatives to bolster the healthcare industry play an essential role in enhancing the global presence of liposomal doxorubicin, thereby propelling its market growth.

Restraints in the Global Liposomal Doxorubicin Market

The global liposomal doxorubicin market may face significant challenges due to various adverse effects associated with the medication. Patients may experience an elevated risk of infections, respiratory difficulties, pallor, easy bruising, frequent nosebleeds, and overall weakness before and after treatment. Additional side effects may include redness, pain, and peeling of the hands and feet, along with symptoms such as weight loss, diarrhea, and fatigue. These complications can deter patient adherence to treatment and may lead to reluctance among healthcare providers to prescribe liposomal doxorubicin, ultimately hindering the growth of the market.

Market Trends of the Global Liposomal Doxorubicin Market

The Global Liposomal Doxorubicin market is witnessing a notable upward trend, primarily driven by the rising incidence of breast cancer, which constitutes a significant portion of cancer diagnoses among women globally. Increasing awareness and advancements in targeted drug delivery systems, coupled with a growing preference for liposomal formulations due to their enhanced bioavailability and reduced side effects, are bolstering market growth. Additionally, ongoing research into the efficacy of liposomal doxorubicin in treating various malignancies beyond breast cancer is further diversifying its application. This evolving landscape indicates a robust potential for sustained expansion in the liposomal doxorubicin sector.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis

Global Liposomal Doxorubicin Market Size by Product Type & CAGR (2026-2033)

Market Overview
Lipodox
Doxil
Myocet

Global Liposomal Doxorubicin Market Size by Application & CAGR (2026-2033)

Market Overview
Breast Cancer
Ovarian Cancer
Multiple Myeloma
Kaposi's Sarcoma
Other Cancers

Global Liposomal Doxorubicin Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Liposomal Doxorubicin Market Size & CAGR (2026-2033)

North America (Product Type, Application, Distribution Channel)
- US
- Canada
Europe (Product Type, Application, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product Type, Application, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product Type, Application, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product Type, Application, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cadila Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SRS Pharmaceuticals Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments